[1] Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine, 2010; 28, 6653−7. doi:  10.1016/j.vaccine.2010.08.037
[2] Carmona G, Vilaró M, Ciruela P, et al. Hepatitis A surveillance: sensitivity of two information sources. BMC Infect Dis, 2018; 18, 633. doi:  10.1186/s12879-018-3552-4
[3] Jacobsen KH. Globalization and the changing epidemiology of hepatitis a virus. Cold Spring Harb Perspect Med, 2018; 8.
[4] Willner IR, Uhl MD, Howard SC, et al. Serious hepatitis a: an analysis of patients hospitalized during an urban epidemic in the united states. Anna Inter Med, 1998; 128, 111−4. doi:  10.7326/0003-4819-128-2-199801150-00006
[5] Koff RS. Hepatitis A. Lancet, 1998; 351, 1643−9. doi:  10.1016/S0140-6736(98)01304-X
[6] Aggarwal R, Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis, 2015; 28, 488−96. doi:  10.1097/QCO.0000000000000188
[7] Parrón I, Planas C, Godoy P, et al. Effectiveness of hepatitis a vaccination as post-exposure prophylaxis. Hum Vaccin Immunother, 2016; 13, 423−7.
[8] Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med, 1992; 327, 453−7. doi:  10.1056/NEJM199208133270702
[9] Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA, 1994; 271, 1328−34. doi:  10.1001/jama.1994.03510410040030
[10] André FE, D'Hondt E, Delem A, et al. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine, 1992; 10, S160−8. doi:  10.1016/0264-410X(92)90576-6
[11] Chen Y, Zhou CL, Zhang XJ, et al. Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine. Vaccine, 2018; 36, 114−21. doi:  10.1016/j.vaccine.2017.11.036
[12] Espul C, Benedetti L, Linares M, et al. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Hum Vaccin Immunother, 2017; 13, 2707−12. doi:  10.1080/21645515.2017.1358326
[13] Luo J, Wang X, Ma F, et al. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study. Clin Microbiol Infect, 2018; 25, 1422−7.
[14] Zhang Z, Zhu X, Hu Y, et al. Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Hum Vaccin Immunother, 2017; 13, 1314−9. doi:  10.1080/21645515.2016.1278329
[15] Mosites E, Gounder P, Snowball M, et al. Hepatitis A vaccine immune response 22 years after vaccination. J Med Virol, 2018; 90, 1418−22. doi:  10.1002/jmv.25197
[16] Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: Long-term follow-up at 15 years. J Med Virol, 2011; 83, 1885−91. doi:  10.1002/jmv.22200
[17] Van Herck K, Crasta PD, Messier M, et al. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother, 2012; 8, 323−7. doi:  10.4161/hv.18617
[18] Chappuis F, Farinelli T, Deckx H, et al. Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine, 2017; 35, 1448−54. doi:  10.1016/j.vaccine.2017.01.031
[19] Plumb ID, Bulkow LR, Bruce MG, et al. Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska. J Viral Hepat, 2017; 24, 608−12. doi:  10.1111/jvh.12676
[20] Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol, 2000; 60, 1−7. doi:  10.1002/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H
[21] Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol, 2001; 63, 1−7. doi:  10.1002/1096-9071(200101)63:1<1::AID-JMV1000>3.0.CO;2-U
[22] Hens N, Habteab Ghebretinsae A, Hardt K, et al. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine, 2014; 32, 1507−13. doi:  10.1016/j.vaccine.2013.10.088
[23] López EL, Contrini MM, Mistchenko A, et al. Modeling the Long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in argentinean children. Pediatr Infect Dis J, 2015; 34, 417−25. doi:  10.1097/INF.0000000000000605
[24] Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine, 2007; 25, 4324−33. doi:  10.1016/j.vaccine.2007.02.069
[25] Andraud M, Lejeune O, Musoro JZ, et al. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus. Plos Comput Biol, 2012; 8, e1002418. doi:  10.1371/journal.pcbi.1002418
[26] Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev, 2010; 236, 125−38. doi:  10.1111/j.1600-065X.2010.00912.x
[27] Ren A, Feng F, Ma J, et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study. Chin Med J (Engl), 2002; 115, 1483−5.
[28] Jiang WP, Chen JT, Wang X, et al. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive®): a double-blind, randomized and controlled trial. Vaccine, 2008; 26, 2297−301. doi:  10.1016/j.vaccine.2007.11.008
[29] Yu C, Song Y, Qi Y, et al. Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study. Hum Vaccin Immunother, 2016; 12, 2595−602. doi:  10.1080/21645515.2016.1197450
[30] Macallan DC, Wallace DL, Zhang Y, et al. B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood, 2005; 105, 3633. doi:  10.1182/blood-2004-09-3740
[31] Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother, 2018; 14, 1370−7. doi:  10.1080/21645515.2018.1442162
[32] López EL, Contrini MM, Mistchenko A, et al. Long-term immunity after two doses of inactivated hepatitis a vaccine, in argentinean children. Pediatr Infect Dis J, 2010; 29.
[33] Honorati MC, Palareti A, Dolzani P, et al. A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Clin Exp Immunol, 1999; 116, 121−6. doi:  10.1046/j.1365-2249.1999.00866.x
[34] Teunis PFM, van der Heijden OG, de Melker HE, et al. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect, 2002; 129, 479−89. doi:  10.1017/S0950268802007896
[35] Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis a virus. J Infect Dis, 1983; 148, 1033−9. doi:  10.1093/infdis/148.6.1033
[36] Melgaço JG, Morgado LN, Santiago MA, et al. A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection. Vaccine, 2015; 33, 3813−20. doi:  10.1016/j.vaccine.2015.06.099
[37] Marshall H, Nolan T, Díez Domingo J, et al. Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Vaccine, 2010; 28, 4411−5. doi:  10.1016/j.vaccine.2010.04.040